BeiGene LTD – HKEX Investor Overview

Our mission is to build the first next-generation biopharmaceutical company — one that expands the highest quality therapies to billions more people — through courage, persistent innovation, and challenging the status quo.

Investor Presentation

Bei 1.PNG
  • February 26, 2024
    Investor Presentation - Q4 & FY 2023
All Documents


  • Feb 29 - Mar 03, 2024
    International Congress on Hematologic Malignancies Poster Presentation from Thursday, February 29th thru Sunday, March 3rd: Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL): A Matching-Adjusted Indirect Comparison (MAIC)
  • Jan 08, 2024
    42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024 at 1:30 pm PST
Events & Presentations

Sustainability at our core

Change Is The Cure is our sustainability and corporate social responsibility platform. It delivers on our mission and codifies the work we are doing to go beyond our life-saving medicines to meet the diverse needs of the global population – from patients and colleagues to investors and the communities in which we serve.

Our global strategy is focused on five areas supported by goals, including:

  • Advancing more new molecules in the clinic each year
  • Increasing the number of women in VP and above positions
  • Reducing our greenhouse gas emissions
  • Engaging more colleagues around the world through volunteerism
  • Operating our business in an ethical manner

We understand that our business plays an important role in creating a more equitable and sustainable world and we are committed to our journey to delivering on that promise.

ESG Report
ESG Presentation

Get in touch

Thank you for your interest in Beigene, Ltd ! You will receive an email shortly. Please confirm your email address by clicking the link inside.

Back to the form